MXPA03008690A - Inhibidores novedosos de tirosina cinasa. - Google Patents

Inhibidores novedosos de tirosina cinasa.

Info

Publication number
MXPA03008690A
MXPA03008690A MXPA03008690A MXPA03008690A MXPA03008690A MX PA03008690 A MXPA03008690 A MX PA03008690A MX PA03008690 A MXPA03008690 A MX PA03008690A MX PA03008690 A MXPA03008690 A MX PA03008690A MX PA03008690 A MXPA03008690 A MX PA03008690A
Authority
MX
Mexico
Prior art keywords
tyrosine kinase
kinase inhibitors
novel tyrosine
novel
inhibitors
Prior art date
Application number
MXPA03008690A
Other languages
English (en)
Spanish (es)
Inventor
G Saulnier Mark
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MXPA03008690A publication Critical patent/MXPA03008690A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA03008690A 2001-03-28 2002-03-26 Inhibidores novedosos de tirosina cinasa. MXPA03008690A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27932701P 2001-03-28 2001-03-28
PCT/US2002/009402 WO2002079192A1 (en) 2001-03-28 2002-03-26 Novel tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
MXPA03008690A true MXPA03008690A (es) 2003-12-12

Family

ID=23068491

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03008690A MXPA03008690A (es) 2001-03-28 2002-03-26 Inhibidores novedosos de tirosina cinasa.

Country Status (25)

Country Link
EP (1) EP1381598A4 (cg-RX-API-DMAC7.html)
JP (1) JP2004534010A (cg-RX-API-DMAC7.html)
KR (1) KR20030083016A (cg-RX-API-DMAC7.html)
CN (1) CN1514833A (cg-RX-API-DMAC7.html)
AR (1) AR035804A1 (cg-RX-API-DMAC7.html)
BG (1) BG108206A (cg-RX-API-DMAC7.html)
BR (1) BR0208373A (cg-RX-API-DMAC7.html)
CA (1) CA2442428A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20032615A3 (cg-RX-API-DMAC7.html)
EE (1) EE200300475A (cg-RX-API-DMAC7.html)
GE (1) GEP20053660B (cg-RX-API-DMAC7.html)
HR (1) HRP20030844A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0400323A2 (cg-RX-API-DMAC7.html)
IL (1) IL158041A0 (cg-RX-API-DMAC7.html)
IS (1) IS6968A (cg-RX-API-DMAC7.html)
MX (1) MXPA03008690A (cg-RX-API-DMAC7.html)
NO (1) NO20034308L (cg-RX-API-DMAC7.html)
PE (1) PE20021015A1 (cg-RX-API-DMAC7.html)
PL (1) PL373300A1 (cg-RX-API-DMAC7.html)
RU (1) RU2003131693A (cg-RX-API-DMAC7.html)
SK (1) SK12002003A3 (cg-RX-API-DMAC7.html)
UY (1) UY27234A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002079192A1 (cg-RX-API-DMAC7.html)
YU (1) YU84603A (cg-RX-API-DMAC7.html)
ZA (1) ZA200307466B (cg-RX-API-DMAC7.html)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7081454B2 (en) * 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
EP1480514A4 (en) 2002-03-01 2008-08-13 Bristol Myers Squibb Co TRANSGENIC NON-HUMAN MAMMALS EXPRESS CONSTITUTIVELY ACTIVATED TYROSINE KINASE RECEPTORS
WO2003106452A2 (en) * 2002-06-12 2003-12-24 Millennium Pharmaceuticals, Inc. Antagonists of melanin concentrating hormone receptor
WO2004050033A2 (en) * 2002-12-02 2004-06-17 Arqule, Inc. Method of treating cancers
EP1581539A4 (en) * 2003-01-03 2007-09-19 Bristol Myers Squibb Co NEW TYROSINE KINASE HEMMER
JP2006516626A (ja) * 2003-01-28 2006-07-06 スミスクライン ビーチャム コーポレーション 化学的化合物
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
US8362017B2 (en) 2003-08-29 2013-01-29 Exelixis, Inc. C-kit modulators and methods of use
US20050075358A1 (en) * 2003-10-06 2005-04-07 Carboni Joan M. Methods for treating IGF1R-inhibitor induced hyperglycemia
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
DE102004010207A1 (de) 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
MXPA06011423A (es) 2004-04-02 2007-01-23 Osi Pharm Inc Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico.
JP2008510734A (ja) 2004-08-18 2008-04-10 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
CA2591413A1 (en) * 2004-12-16 2006-06-22 Vertex Pharmaceuticals Incorporated Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
WO2006130657A2 (en) 2005-05-31 2006-12-07 Bristol-Myers Squibb Company Stereoselective reduction process for the preparation of pyrrolotriazine compounds
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
PL1910384T3 (pl) 2005-08-04 2013-03-29 Sirtris Pharmaceuticals Inc Pochodne imidazo[2,1-b]tiazolu jako związki modulujące sirtuinę
JP5112317B2 (ja) * 2005-08-29 2013-01-09 バーテックス ファーマシューティカルズ インコーポレイテッド 非受容体型チロシンキナーゼのtecファミリーの阻害剤として有用な3,5−二置換ピリド−2−オン
EP1919906B1 (en) 2005-08-29 2011-10-12 Vertex Pharmaceuticals Incorporated 3, 5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
ATE548363T1 (de) * 2005-08-29 2012-03-15 Vertex Pharma 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen
WO2007026720A1 (ja) * 2005-08-31 2007-03-08 Taisho Pharmaceutical Co., Ltd. 縮環ピラゾール誘導体
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
WO2007145203A1 (ja) * 2006-06-13 2007-12-21 Daiichi Fine Chemical Co., Ltd. 光学活性2-アミノ-1-(4-フルオロフェニル)エタノール
US8063225B2 (en) * 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
WO2008022747A1 (en) * 2006-08-21 2008-02-28 F. Hoffmann-La Roche Ag Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents
WO2008025526A1 (en) * 2006-08-31 2008-03-06 F. Hoffmann-La Roche Ag Indole derivatives, their manufacture and use as pharmaceutical agents
US8492328B2 (en) 2007-05-17 2013-07-23 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
CN101687840A (zh) * 2007-06-25 2010-03-31 霍夫曼-拉罗奇有限公司 作为激酶抑制剂的苯并咪唑酰胺基衍生物
EP2065380A1 (en) * 2007-08-22 2009-06-03 F.Hoffmann-La Roche Ag Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer
US7816540B2 (en) * 2007-12-21 2010-10-19 Hoffmann-La Roche Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives
CA2712959C (en) 2008-01-22 2015-06-23 Vernalis (R & D) Ltd Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity
WO2009143051A1 (en) 2008-05-19 2009-11-26 Osi Pharmaceuticals, Inc. Substituted imidazopyr-and imidazotri-azines
PE20120057A1 (es) 2008-12-19 2012-02-24 Sirtris Pharmaceuticals Inc Compuestos de tiazolopiridina moduladores de sirtuina
DE102010001064A1 (de) * 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
KR20120020099A (ko) 2009-04-20 2012-03-07 오에스아이 파마슈티컬스, 엘엘씨 C-피라진-메틸아민의 제조
US8536180B2 (en) * 2009-05-27 2013-09-17 Abbvie Inc. Pyrimidine inhibitors of kinase activity
US20120220594A1 (en) 2009-10-30 2012-08-30 Bristol-Meyers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
EP3170813B1 (en) * 2010-10-06 2018-12-12 GlaxoSmithKline LLC Benzimidazole derivatives as pi3 kinase inhibitors
US8772304B2 (en) * 2010-11-01 2014-07-08 Boehringer Ingelheim International Gmbh Benzimidazole inhibitors of leukotriene production
EP2766497A1 (en) 2011-10-13 2014-08-20 Bristol-Myers Squibb Company Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
KR102307566B1 (ko) 2013-06-21 2021-10-05 제니쓰 에피제네틱스 리미티드 신규한 바이사이클릭 브로모도메인 억제제
US9662311B2 (en) 2013-06-21 2017-05-30 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
US9855271B2 (en) 2013-07-31 2018-01-02 Zenith Epigenetics Ltd. Quinazolinones as bromodomain inhibitors
CN103936719A (zh) * 2014-05-14 2014-07-23 中国药科大学 苯并咪唑类衍生物制备方法及用途
US11920164B2 (en) 2014-07-30 2024-03-05 Yeda Research And Development Co. Ltd. Media for culturing naive human pluripotent stem cells
EP3227281A4 (en) 2014-12-01 2018-05-30 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
EP3233846A4 (en) 2014-12-17 2018-07-18 Zenith Epigenetics Ltd. Inhibitors of bromodomains
CN107531697A (zh) * 2015-04-16 2018-01-02 默克专利股份公司 3‑(1h‑苯并咪唑‑2‑基)‑1h‑吡啶‑2‑酮衍生物
EP3914698B1 (en) 2019-01-23 2024-12-11 Yeda Research and Development Co. Ltd Culture media for pluripotent stem cells
CN117069696B (zh) * 2023-08-17 2024-04-26 中国药科大学 一种双靶点小分子抑制剂及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
ATE301651T1 (de) * 1999-06-23 2005-08-15 Aventis Pharma Gmbh Substituierte benzimidazole
US7081454B2 (en) * 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors

Also Published As

Publication number Publication date
UY27234A1 (es) 2002-10-31
BR0208373A (pt) 2005-02-22
IS6968A (is) 2003-09-26
AR035804A1 (es) 2004-07-14
EP1381598A4 (en) 2008-03-19
PL373300A1 (en) 2005-08-22
JP2004534010A (ja) 2004-11-11
HUP0400323A2 (hu) 2005-11-28
RU2003131693A (ru) 2005-05-10
NO20034308D0 (no) 2003-09-26
CA2442428A1 (en) 2002-10-10
SK12002003A3 (en) 2004-10-05
PE20021015A1 (es) 2002-11-10
BG108206A (bg) 2004-11-30
YU84603A (sh) 2006-03-03
KR20030083016A (ko) 2003-10-23
CN1514833A (zh) 2004-07-21
GEP20053660B (en) 2005-11-10
NO20034308L (no) 2003-11-26
ZA200307466B (en) 2005-01-13
CZ20032615A3 (en) 2004-03-17
HRP20030844A2 (en) 2005-08-31
IL158041A0 (en) 2004-03-28
EP1381598A1 (en) 2004-01-21
WO2002079192A1 (en) 2002-10-10
EE200300475A (et) 2004-02-16

Similar Documents

Publication Publication Date Title
MXPA03008690A (es) Inhibidores novedosos de tirosina cinasa.
ZA200202985B (en) Tyrosine kinase inhibitors.
AU2003299651A8 (en) Tyrosine kinase inhibitors
ZA200206386B (en) Kinase inhibitors.
AU2002361577A1 (en) Tyrosine kinase inhibitors
MXPA03009847A (es) Inhibidores de cinasa derivados de pirazol.
AU2002334355A1 (en) Protein tyrosine kinase inhibitors
AU2003298942A8 (en) Tyrosine kinase inhibitors
EP1581539A4 (en) NEW TYROSINE KINASE HEMMER
AU2003282891A8 (en) Novel tyrosine kinases inhibitors
AU2003275282A8 (en) Novel tyrosine kinase inhibitors
AU2002348394A1 (en) Tyrosine kinase inhibitors
MXPA03007310A (es) Derivados de ftalazinona piperidino como inhibidores pde4.
AU2002348020A1 (en) Tyrosine kinase inhibitors
AU2002348393A1 (en) Tyrosine kinase inhibitors
AU2002323406A1 (en) Tyrosine kinase inhibitors
AU2002327534A1 (en) Tyrosine kinase inhibitors
AU2002253350A1 (en) 4-aminosulfonylquinazolines and -quinolines as tyrosine kinase inhibitors
GB0201384D0 (en) Tyrosine kinase inhibitors
HK1060577A (en) Novel tyrosine kinase inhibitors
AU2002326865A1 (en) Tyrosine kinase inhibitors
AU2002322568A1 (en) Tyrosine kinase inhibitors
AU2002337972A1 (en) Tyrosine kinase inhibitors
AU2002304001A1 (en) Tyrosine kinase inhibitors
AU2002326466A1 (en) Tyrosine kinase inhibitors